Skip to main content

Table 2 Baseline characteristics

From: Differences in presentation of symptoms between women and men with intermittent claudication

  Group 1(IC) Group 2 (Control) Group 3(Follow-up IC)
  Men
(N = 153)
(46.0%)
Women
(N = 180)
(54.0%)
Men
(N = 1579)
(47.7%)
Women
(N = 1734)
(52.3%)
Men
(N = 37)
(42.1%)
Women
(N = 51)
(58.0%)
Age
Mean (Std.dev.)
76.3(8.1) 77.0(7.8) 69.9(7.3) 70.6(7.6) 78.7(8.12) 77.5(7.96)
ABI
Median (IQR)
0.72(0.19) 0.71(0.29) 1.07(0.14) 1.00(0.10) 0.69 (0.21) 0.71 (0.29)
(p-value)*** (0.438) (< .001) (0.74)
Concomittant diseases
N (%)
Diabetes n = 3646 42 (27.5) 32 (17.8) 125 (7.9) 119 (6.9) 9 (25.0) 4 (7.7)
(p-value)** (0.047) (.258) (0.033)
Hypertension
n = 3646
86 (56.2) 97 (53.9) 494(31.3) 592(34.1) 19 (52.8) 31 (59.6)
(p-value)** (0.740) (0.082) (0.662)
Stroke
n = 3646
38 (24.8) 12 (6.7) 103 (6.5) 76 (4.4) 9 (25.0) 3 (5.8)
(p-value)** (< 0.001) (0.007) (0.013)
CAD#
n = 3646
26 (17.0) 8 (4.4) 271 (17.2) 222 (12.8) 6 (16.7) 3 (5.8)
(p-value)** (< 0.001) (< 0.001) (0.151)
Medication use
N (%)
Anti-platelet
therapy, n = 2380
134 (99.3) 151 (96.8) 868 (91.5) 1066 (93.5) 34 (100) 47 (97.9)
(p-value)** (0.221) (0.079) (1.00)
Lipidlowering therapy, n = 2380 53 (39.3) 45 (28.9) 238 (25.1) 214 (18.8) 12 (35.3) 13 (27.1)
(p-value)** (0.064) (< 0.001) (0.472)
ACE-inhib. Betablockers n = 2380 73 (54.7) 82 (52.6) 420 (44.3) 397 (34.8) 25 (73.5) 28 (58.3)
(p-value)** (0.815) (< 0.001) (0.170)
WIQ subscales
WIQ distance* 44.6 36.1 100.0 100.0 34.5 40.3
(p-value)*** (0.121)   (0.833)
WIQ speed* 26.1 21.7 89.1 68.5 20.7 23.9
(p-value)*** (0.013) (< 0.001) (0.860)
WIQ stairs* 43.8 41.7 100.0 87.5 41.7 37.5
(p-value)*** (0.13) (< 0.001) (0.937)
Smoking ever
N (%)
Yes 119 (77.8) 89 (49.4) 968 (61.3) 716 (41.3) 26 (72.2) 29 (55.8)
(p-value) *** (< 0.001) (< 0.001) (0.179)